⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Nouveau Biosciences, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Nouveau Biosciences, Inc.
↗Scarsdale, New York, USA
Nouveau Biosciences is a biotechnology company focused on oncology drug discovery and development. The company utilizes a proprietary platform that integrates synthetic lethality, genomics, computational biology, and polymer-based nanochemistry to engineer precision-targeted cancer therapeutics.
Their approach aims to improve drug targeting, tolerability, and efficacy by delivering optimized drug combinations directly to cancer cells. The company's lead asset, Kromastat (formerly NBS-M001), is a clinic-ready nanomedicine targeting indications such as pancreatic cancer, AML, and T-cell malignancies.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Ownership:private
Status:operating
PIPELINE
Stage:Preclinical
Lead Drug Stage:Clinic-ready
Modalities:Nanomedicine, Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Ardena (Manufacturing partnership for Kromastat), University of Virginia (Licensing agreements), CanceRx (Memorandum of Understanding for funding/development)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Owen A. O'Connor - CEO and Chairman
Scientific Founders:Owen A. O'Connor
LINKS
Website:nouveaubiosciences.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Nouveau Biosciences, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.